PCRX Stock Analysis: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$23.51
0.80 (3.52%)
▲
5d:
+3.39%
30d:
+0.13%
90d:
+3.8%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$46.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$29.11
19.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $23.51, which is considered slightly high relative to its 30-day fair value range of $22.48 to $23.55. The stock's valuation (Forward PE: 6.4) is in line with its historical norms (6.6). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $24.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.67 (+26.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $24.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.67 (+26.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$22.48 -
$23.55
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.0%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 26.2% below Wall St target ($29.67)
Trading Range Analysis
30-Day Trading Range
$22.48 -
$23.55
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$22.00
Resistance Level
$24.03
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.44
Wall Street Target
$29.67
(+26.2%)
Revenue Growth (YoY)
5.0%
Earnings Growth (YoY)
-30.0%
Profit Margin
0.7%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
6.4 vs 6.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$23.27
(-1%)
2-Year Target
$23.04
(-2%)
3-Year Target
$22.81
(-3%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$23.36
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 26.8%)
$161.94
(+589%)
Base:
(SPY PE: 6.4, Growth: 26.8%)
$47.92
(+104%)
Bear:
(PE: 5.5, Growth: 26.8%)
$40.73
(+73%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Forward PE: 7.61 | Forward EPS (Implied): $3.09
Bull Case
$28.39
(+21%)
Analyst growth 15.0%, PE expands to 8.0
Base Case
$23.51
(0%)
Market implied 0.0%, PE stable at 7.6
Bear Case
$17.99
(-24%)
Severe decline -15.0%, PE contracts to 6.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.4 to 6.6
Stabilization Target:
$24.08
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: June 24, 2026 9:45 AM ET
Data refreshes hourly during market hours. Next update: 10:45 AM
Data refreshes hourly during market hours. Next update: 10:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
